What are the indications and effects of ruxolitinib tablets/ruxolitinib?

Ruxolitinib tablets/ruxolitinib (JAKAVI) is a selective inhibitor of JAK1 and JAK2 protein tyrosine kinases. It is mainly used to treat myeloproliferative diseases related to abnormal activation of the JAK-STAT pathway. This pathway plays a key role in regulating cytokine signaling, hematopoietic cell differentiation, and immune responses. Once abnormally activated, it can lead to excessive cell proliferation and inflammatory states, and then develop into diseases represented by myelofibrosis (MF) and polycythemia vera (PV). By inhibiting this signaling pathway, JAKAVI can effectively control disease progression and relieve symptoms.

Currently,JAKAVI is widely used in patients with intermediate- and high-risk myelofibrosis, whether primary or secondary to polycythemia vera or essential thrombocythemia. In such patients, ruxolitinib can significantly reduce spleen volume and improve symptoms such as abdominal distension, early satiety, weight loss, and fatigue caused by splenomegaly. At the same time, it can also inhibit the release of a variety of pro-inflammatory cytokines, thereby relieving systemic discomfort caused by chronic inflammation, such as night sweats, bone pain, and itching.

In patients with polycythemia vera, JAKAVI is often used in patients who are refractory to or intolerant to hydroxyurea. The drug not only effectively controls blood cell counts, but also reduces the risk of thrombotic events and improves microvascular symptoms such as headaches, blurred vision, and numbness in the limbs. More importantly, the mechanism of action of JAKAVI is by fundamentally regulating the pathological process driven by JAK2 mutations, so it has a certain biological basis in inhibiting disease progression and is not limited to symptomatic treatment.

In recent years,JAKAVI’s indications have been gradually expanded, including some inflammatory diseases and graft-versus-host disease (GVHD), which also reflects its potential to broadly regulate the immune system. Although these new indications are still in the further research and approval stages, they have laid the foundation for the application of this drug in more disease areas.

Reference materials:https://www.jakavi.com/